Search Medical Condition
Please enter condition
Please choose location from dropdown

Oviedo, Asturias, Spain Clinical Trials

A listing of Oviedo, Asturias, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (106) clinical trials

A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC

Worldwide, intra-arterial therapies are the mainstay of the treatment of patients with HCC in the intermediate stage or in the advanced stage because of portal vein invasion. While transarterial chemoembolization (TACE) is the most widely applied intra-arterial therapy, not all patients in the intermediate stage are good candidates for this ...

Phase

0.0 miles

Learn More »

Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab

Multicenter, non- randomized, open-label, double agent, phase II study of the Spanish Group of CLL (GELLC). Patients with untreated CLL/SLL. Ibrutinib will be administered orally 420 mg (3 x 140 mg capsules) once daily on a continuous schedule on an outpatient basis until disease progression or unacceptable toxicity. After 12 ...

Phase

0.0 miles

Learn More »

Longitudinal Study to Identify Predictive Factors of Post-thrombotic Pulmonary Hypertension

Rationale Pulmonary hypertension (PH) post pulmonary thromboembolisms is a serious and complex disease, is one major cause of pulmonary hypertension (1). It is the most feared late complication of pulmonary thromboembolism (PT) characterized by the organization of thrombotic material within the pulmonary arteries (2). Although a purely mechanical theory is ...

Phase N/A

0.0 miles

Learn More »

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Phase II/III, prospective, multicenter, randomized (1:1), double-blind study to evaluate the efficacy and tolerability of axitinib in patients diagnosed with advanced G1-G2 neuroendocrine tumors (WHO 2010) of nonpancreatic origin that have presented documented disease progression in the 12 months prior to entering the study. In the first part of the ...

Phase

0.0 miles

Learn More »

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

In this protocol the term high-risk neuroblastoma refers to children with either disseminated disease (INSS stage 4: about 40 to 50% of all neuroblastoma) over the age of one or INSS stage 2 and 3 disease with amplification of the MycN proto-oncogene Between 10% and 20% of children with stage ...

Phase

0.0 miles

Learn More »

European Low and Intermediate Risk Neuroblastoma Protocol

LOW RISK STUDY The low risk group of patients includes NB patients without MYCN amplification with or without life threatening symptoms in the following clinical situations: Children aged 18 months with localised neuroblastoma associated with image defined risk factors precluding upfront surgery (stage INRG L2). Children aged 12 months with ...

Phase

0.0 miles

Learn More »

International Guillain-Barr Syndrome Outcome Study

GBS is a post-infectious immune-mediated polyradiculoneuropathy with a highly diverse clinical course and outcome despite partially effective forms of treatment(immunoglobulins and plasma exchange). Outcome in patients with GBS has not improved in the last two decades. At present about 10 to 20% of patients remain severely disabled and about 5% ...

Phase N/A

0.0 miles

Learn More »

PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years

Prephase (days -5 to -1) Dexamethasone 10 mg/m2 bolus day EV for 5 days (-5 to -1). Supplementary treatment: hydration minimum 2000 ml / day. allopurinol 300 mg / day. gastric protection (as center). daily monitoring of blood glucose daily monitoring of renal function. Intrathecal treatment (diagnosis and prophylactic / ...

Phase

0.0 miles

Learn More »

Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE

Induction Chemotherapy Vincristine (VCR): 1.5 mg/m2 (maximum dose 2 mg) iv days 1, 8, 15 and 22 daunorubicin (DNR) 45 mg/m2 i.v. days 1, 8, 15 and 22 Prednisone (PDN): 60 mg/m2 per day, i.v. or p.o., days 1-27 Imatinib 600 mg p.o. from day 1 until the beginning of ...

Phase

0.0 miles

Learn More »

Lysosomal Acid Lipase (LAL) Deficiency Registry

Lysosomal Acid Lipase (LAL) Deficiency is a rare autosomal recessive lysosomal storage disorder (LSD) that is caused by a marked decrease of lysosomal acid lipase (LAL), the enzyme that breaks down cholesteryl esters and triglycerides in the lysosomes. Lysosomal Acid Lipase Deficiency presenting in infants (historically called Wolman Disease) is ...

Phase N/A

0.0 miles

Learn More »